Anna L.
- Country
- Spain
- Department
- Pediatric in Oncology and Hematology
Research Overview
- Evaluation of Chemotherapy Regimens Including Cisplatin, Cyclophosphamide, and Etoposide in Pediatric and Young Adult Ependymoma Treatment
- An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy
Data & Insights
Has run more than one trial at 56 of 155 partner sites.
Specializations
Pediatric Solid Tumors
Focused on malignant growths arising in children, including neuroblastoma, sarcoma, and glioma, with an emphasis on innovative therapeutic strategies.
- High‑risk neuroblastoma trials
- Soft‑tissue sarcoma protocols
- Pediatric brain tumor targeted studies
- Rare pediatric solid‑tumor registries
Collaboration with multidisciplinary teams at Hospital Vall d’Hebron supports rapid translation of novel agents into pediatric practice.
Pediatric Hematologic Malignancies
Specializes in blood‑derived cancers of the young, such as acute lymphoblastic leukemia, acute myeloid leukemia, and pediatric lymphoma, aiming to improve survival and reduce treatment toxicity.
- Front‑line ALL risk‑adapted therapy
- AML with measurable residual disease monitoring
- Burkitt and diffuse large B‑cell lymphoma studies
- Genetic profiling for pediatric leukemias
Integration of molecular diagnostics guides personalized treatment pathways for children with hematologic cancers.
Bone Marrow Transplant & Cellular Therapy
Leads programs in hematopoietic stem cell transplantation and emerging cellular modalities, addressing challenges such as graft‑versus‑host disease and CAR‑T cell applications in pediatric patients.
- Allogeneic HSCT conditioning optimization
- CAR‑T cell therapy for refractory B‑cell malignancies
- Prophylaxis and treatment of acute GVHD
- Immune reconstitution monitoring post‑transplant
These efforts aim to expand curative options for children who relapse after conventional chemotherapy.
Targeted Molecular Oncology
Investigates molecular drivers across pediatric cancers, including IDH‑mutant gliomas, KRAS‑altered solid tumors, and HER2‑positive disease, to align patients with biomarker‑guided therapies.
- IDH inhibitor trials in pediatric glioma
- KRAS G12C targeted agents for solid tumors
- HER2‑directed antibody‑drug conjugates
- Biomarker‑driven basket studies
Strategic partnerships enable rapid access to cutting‑edge agents for children with actionable mutations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.